{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:59:55Z","timestamp":1791575995775,"version":"4.3.4"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020703","name":"Department of Pharmaceutical Sciences, St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.canlet.2024.217061","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T09:31:47Z","timestamp":1718271107000},"page":"217061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies"],"prefix":"10.1016","volume":"597","author":[{"given":"Lu-Qi","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217061_bib1","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201606","article-title":"Cancer focus: lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217061_bib2","unstructured":"Cancer Statistics Center - American Cancer Society, (n.d.). https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.241517963.864784433.1714434316-544842622.1714245192&_gl=1*90ebhk*_ga*NTQ0ODQyNjIyLjE3MTQyNDUxOTI.*_ga_12CJLLFFQT*MTcxNDQzNDMxNS40LjEuMTcxNDQzNDYyOC42MC4wLjA. (accessed April 28, 2024)."},{"key":"10.1016\/j.canlet.2024.217061_bib3","unstructured":"Liver and intrahepatic bile duct Statistics | American Cancer Society - Cancer Facts & Statistics, (n.d.). https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.233684126.1618493161.1661459795-474758943.1645215909&_gac=1.251856763.1661463841.CjwKCAjwu5yYBhAjEiwAKXk_eHqPKxKiy5hHMLnmUKVM8bpxHCoeq8_L7At0fTIPcWPkWjWg_JNjHhoCRLgQAvD_BwE#!\/cancer-site\/Liver20and20intrahepatic20bile20duct (accessed September 28, 2023)."},{"key":"10.1016\/j.canlet.2024.217061_bib4","unstructured":"Liver Cancer: Statistics | Cancer News, (n.d.). https:\/\/www.cancer.net\/cancer-types\/liver-cancer\/statistics (accessed September 28, 2023)."},{"key":"10.1016\/j.canlet.2024.217061_bib5","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel Mph","year":"2023","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2024.217061_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","article-title":"The immunological and metabolic landscape in primary and metastatic liver cancer","volume":"21","author":"Li","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib7","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI127201","article-title":"Adipocyte and lipid metabolism in cancer drug resistance","volume":"129","author":"Cao","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217061_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: from mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2024.217061_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7150\/ijbs.42300","article-title":"Aldehyde Dehydrogenase, liver disease and cancer","volume":"16","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216512","article-title":"The lipid metabolism remodeling: a hurdle in breast cancer therapy","volume":"582","author":"Xiao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216220","article-title":"Advances in lipid-based carriers for cancer therapeutics: liposomes, exosomes and hybrid exosomes","volume":"565","author":"Moholkar","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S0007114520001208","article-title":"Diet and liver cancer risk: a narrative review of epidemiological evidence","volume":"124","author":"Yang","year":"2020","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.canlet.2024.217061_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","article-title":"Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: how can outcomes Be improved?","volume":"15","author":"Lencioni","year":"2010","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217061_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","article-title":"Hepatocellular carcinoma: from diagnosis to treatment","volume":"25","author":"Grandhi","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.canlet.2024.217061_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071715","article-title":"Hypoxia, metabolic reprogramming, and drug resistance in liver cancer","volume":"10","author":"Bao","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.217061_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061370","article-title":"Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment","volume":"9","author":"Pi\u00f1ero","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.217061_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","article-title":"Hepatocellular carcinoma: new developments","volume":"27","author":"Ganesan","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/bs.acr.2020.12.001","article-title":"Systemic therapy of liver cancer","volume":"149","author":"Demir","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217061_bib20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ueg2.12286","article-title":"New concepts in the treatment of hepatocellular carcinoma","volume":"10","author":"Sidali","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.canlet.2024.217061_bib21","doi-asserted-by":"crossref","DOI":"10.21037\/cco-20-89","article-title":"Efficacy and safety of radiotherapy for primary liver cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib22","first-page":"398","article-title":"Advances and future directions in the treatment of hepatocellular carcinoma","volume":"13","author":"Gosalia","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050901","article-title":"Hepatocellular carcinoma: old and emerging therapeutic targets","volume":"16","author":"Pessino","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217061_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2024.217061_bib26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib27","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.2217\/fon-2022-0652","article-title":"Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma","volume":"18","author":"De Castria","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113690","article-title":"Treatment for liver cancer: from sorafenib to natural products","volume":"224","author":"Man","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.217061_bib29","article-title":"New insights on sorafenib resistance in liver cancer with correlation of individualized therapy","volume":"1874","author":"Cheng","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2024.217061_bib30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.canlet.2024.217061_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5582\/bst.2021.01091","article-title":"Conversion therapy and maintenance therapy for primary hepatocellular carcinoma","volume":"15","author":"Zhou","year":"2021","journal-title":"Biosci Trends"},{"key":"10.1016\/j.canlet.2024.217061_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2024.217061_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216352","article-title":"Fatty acids in cancer chemoresistance","volume":"572","author":"Qin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216267","article-title":"Lipid metabolism reprogramming of CD8+ T cell and therapeutic implications in cancer","volume":"567","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101041","article-title":"The promising role of tumor-associated macrophages in the treatment of cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.217061_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mito.2018.02.009","article-title":"Mitochondrial \u03b2-oxidation of saturated fatty acids in humans","volume":"46","author":"Adeva-Andany","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.canlet.2024.217061_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168969","article-title":"Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPAR\u03b1","volume":"22","author":"Tahri-Joutey","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-60204-8_1","article-title":"Peroxisome: metabolic functions and biogenesis","volume":"1299","author":"Okumoto","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2024.217061_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081943","article-title":"Lipid metabolism in glioblastoma: from de novo synthesis to storage","volume":"10","author":"Kou","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2024.217061_bib44","article-title":"Key events in cancer: dysregulation of SREBPs","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217061_bib45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","article-title":"Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma","volume":"12","author":"Du","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2024.217061_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0083-6729(02)65064-2","article-title":"Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism","volume":"65","author":"Shimano","year":"2002","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.canlet.2024.217061_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01510","article-title":"Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy","volume":"10","author":"Xue","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib48","article-title":"Targeting SREBP-1-mediated lipogenesis as potential strategies for cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/1568026618666180523104541","article-title":"SCAP\/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy","volume":"18","author":"Cheng","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.canlet.2024.217061_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1884-7","article-title":"SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity","volume":"10","author":"Yin","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1749-6632.2002.tb04261.x","article-title":"Sterol regulatory element-binding proteins (SREBPs) as regulators of lipid metabolism: polyunsaturated fatty acids oppose cholesterol-mediated induction of SREBP-1 maturation","volume":"967","author":"Kim","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2024.217061_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119984","article-title":"Crosstalk between miRNA and PI3K\/AKT\/mTOR signaling pathway in cancer","volume":"285","author":"Akbarzadeh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14728222.2019.1615883","article-title":"Aberrant lipid metabolism as a therapeutic target in liver cancer","volume":"23","author":"Pope","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2024.217061_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593017","article-title":"Deregulation of lipid metabolism: the critical factors in ovarian cancer","volume":"10","author":"Ji","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib56","article-title":"Unveiling the MUFA-cancer connection: insights from endogenous and exogenous perspectives","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","article-title":"Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis","volume":"9","author":"Sen","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: where do we stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2024.217061_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2024.217061_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14728222.2017.1381087","article-title":"Fatty acid synthase (FASN) as a therapeutic target in breast cancer","volume":"21","author":"Menendez","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2024.217061_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25173935","article-title":"Fatty acid synthase: an emerging target in cancer","volume":"25","author":"Fhu","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2024.217061_bib62","article-title":"Key molecules of fatty acid metabolism in gastric cancer","volume":"12","author":"Li","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.canlet.2024.217061_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110447","article-title":"Lipid metabolic reprogramming in hepatocellular carcinoma","volume":"10","author":"Nakagawa","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217061_bib64","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02567-z","article-title":"Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217061_bib66","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O'Farrell","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217061_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1574892818666230112170003","article-title":"Fatty acid synthase (FASN): a patent review since 2016-present","volume":"19","author":"Singh","year":"2023","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"10.1016\/j.canlet.2024.217061_bib68","article-title":"Targeting acetyl-CoA carboxylase 1 for cancer therapy","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217061_bib69","article-title":"Acetyl-CoA carboxylases and diseases","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib70","first-page":"2499","volume":"vol. 25","author":"Shen","year":"2023"},{"key":"10.1016\/j.canlet.2024.217061_bib71","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2019.1657825","article-title":"Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1\/2 inhibitors","volume":"28","author":"Chen","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2024.217061_bib72","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/14737140.2015.1038246","article-title":"The acetyl-CoA carboxylase enzyme: a target for cancer therapy?","volume":"15","author":"Wang","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2024.217061_bib73","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1158\/1538-7445.AM2016-3781","article-title":"Abstract 3781: combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma","volume":"76","author":"Wei","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217061_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2019.12.010","article-title":"ATP citrate lyase: a central metabolic enzyme in cancer","volume":"471","author":"Icard","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib75","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-11-4112","article-title":"ATP-citrate lyase: a key player in cancer metabolism","volume":"72","author":"Zaidi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217061_bib76","doi-asserted-by":"crossref","first-page":"951","DOI":"10.7150\/jca.52778","article-title":"Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma","volume":"13","author":"Sun","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2018.00038","article-title":"Autophagic regulation of lipid homeostasis in cardiometabolic syndrome","volume":"5","author":"Yang","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.canlet.2024.217061_bib78","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.gastro.2015.09.042","article-title":"Regulation of liver metabolism by autophagy","volume":"150","author":"Madrigal-Matute","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.217061_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.biopha.2017.07.168","article-title":"Lipophagy and liver disease: new perspectives to better understanding and therapy","volume":"97","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.217061_bib80","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217061_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13010101","article-title":"Metabolic role of autophagy in the pathogenesis and development of NAFLD","volume":"13","author":"An","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.canlet.2024.217061_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082195","article-title":"Regulation of autophagy via carbohydrate and lipid metabolism in cancer","volume":"15","author":"Alizadeh","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217061_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00431","article-title":"Interplay between lipid metabolism and autophagy","volume":"8","author":"Xie","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.217061_bib84","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.1601920","article-title":"PPAR-\u0391 activation mediates innate host defense through induction of TFEB and lipid catabolism","volume":"198","author":"Kim","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217061_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12935-017-0451-5","article-title":"The role of ppar\u03b3 and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation","volume":"17","author":"Assump\u00e7\u00e3o","year":"2017","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2024.217061_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/1751-2980.13220","article-title":"Increased expression of autophagy-related gene 5 indicates poor prognosis in patients with hepatocellular carcinoma","volume":"24","author":"Guo","year":"2023","journal-title":"J Dig Dis"},{"key":"10.1016\/j.canlet.2024.217061_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101158","article-title":"Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer","volume":"14","author":"Cho","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.canlet.2024.217061_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib89","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217061_bib90","first-page":"1","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canlet.2024.217061_bib91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.canlet.2024.217061_bib92","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib93","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canlet.2024.217061_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"6258","key":"10.1016\/j.canlet.2024.217061_bib95","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/343555a0","article-title":"Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma","volume":"343","author":"Wang","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217061_bib96","unstructured":"Epidemiology and risk factors for hepatocellular carcinoma - UpToDate, (n.d.). https:\/\/www.uptodate.com\/contents\/epidemiology-and-risk-factors-for-hepatocellular-carcinoma (accessed September 28, 2023)."},{"key":"10.1016\/j.canlet.2024.217061_bib97","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.3748\/wjg.v27.i26.4182","article-title":"Prevention of vertical transmission of hepatitis B virus infection","volume":"27","author":"Veronese","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2024.217061_bib98","first-page":"153","article-title":"Current management of hepatocellular carcinoma","volume":"10","author":"Crissien","year":"2014","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2024.217061_bib101","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D\u2019souza","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2024.217061_bib102","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217061_bib104","first-page":"7","article-title":"WHO, Epidemiological update: increasing mortality calls for action 03","volume":"2017","year":"2017","journal-title":"Global Hepatitis Report"},{"key":"10.1016\/j.canlet.2024.217061_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life11020169","article-title":"HBV\/HDV Co-infection: epidemiological and clinical changes, recent knowledge and future challenges","volume":"11","author":"Sagnelli","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.canlet.2024.217061_bib106","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib107","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"B\u00e9guelin","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2018.07.005","article-title":"Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia","volume":"74","author":"Coghill","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib109","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.217061_bib110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigveh\u00ed","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.canlet.2024.217061_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073897","article-title":"Viral hepatitis, cholesterol metabolism, and cholesterol-lowering natural compounds","volume":"23","author":"Liou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib112","article-title":"Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.canlet.2024.217061_bib113","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/biology3040892","article-title":"Hepatitis C virus life cycle and lipid metabolism","volume":"3","author":"Popescu","year":"2014","journal-title":"Biology"},{"key":"10.1016\/j.canlet.2024.217061_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1136-y","article-title":"Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK\/SREBP-1c signaling","volume":"18","author":"Meng","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bjc.2014.579","article-title":"Alcohol consumption and site-specific cancer risk: a comprehensive dose\u2013response meta-analysis","volume":"112","author":"Bagnardi","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib116","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(21)00279-5","article-title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","volume":"22","author":"Rumgay","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib117","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.32355","article-title":"Declining disease burden of HCC in the United States, 1992-2017: a population-based analysis","volume":"76","author":"Han","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib118","unstructured":"Aicr, WCRF, Diet, Nutrition, Physical Activity and Liver Cancer, (n.d.)."},{"key":"10.1016\/j.canlet.2024.217061_bib119","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","article-title":"Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies","volume":"25","author":"Turati","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.11.045","article-title":"Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis","volume":"58","author":"Lin","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib121","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2018.10.037","article-title":"Effect of ethanol on lipid metabolism","volume":"70","author":"You","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115717","article-title":"Pathophysiological aspects of alcohol metabolism in the liver","volume":"22","author":"Hyun","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib123","article-title":"Evidence for involvement of the alcohol consumption WDPCP gene in lipid metabolism, and liver cirrhosis","volume":"13","author":"O'Farrell","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217061_bib124","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"Jeon","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.canlet.2024.217061_bib125","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.217061_bib126","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"MacHado","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.217061_bib127","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.canlet.2024.217061_bib128","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217061_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216048","article-title":"Human liver cancer organoids: biological applications, current challenges, and prospects in hepatoma therapy","volume":"555","author":"Chen","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib131","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.canlet.2024.217061_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep46658","article-title":"Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients","volume":"7","author":"Chiappini","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217061_bib133","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4020249","article-title":"An overview of lipid metabolism and nonalcoholic fatty liver disease","volume":"2020","author":"Pei","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2024.217061_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.canlet.2024.217061_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.217061_bib136","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MCG.0b013e3182a030c4","article-title":"The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis","volume":"48","author":"Jinjuvadia","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.canlet.2024.217061_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/15330338221119743","article-title":"Cancer of the liver and its relationship with diabetes mellitus","volume":"21","author":"Onikanni","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2024.217061_bib138","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217061_bib139","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature01137","article-title":"A central role for JNK in obesity and insulin resistance","volume":"420","author":"Hirosumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217061_bib140","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-017-0851-x","article-title":"Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis","volume":"17","author":"Wainwright","year":"2017","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.canlet.2024.217061_bib141","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/carcin\/23.11.1781","article-title":"The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma","volume":"23","author":"Hu","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2024.217061_bib142","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00125-018-4664-5","article-title":"Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events","volume":"61","author":"Ohkuma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.canlet.2024.217061_bib143","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2014 viewpoint of the IARC working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217061_bib144","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5762395","article-title":"Lipid-induced mechanisms of metabolic syndrome","volume":"2020","author":"Denisenko","year":"2020","journal-title":"J Obes"},{"issue":"1","key":"10.1016\/j.canlet.2024.217061_bib145","first-page":"1","article-title":"Association of lipid composition and unsaturated fatty acids of VLDL with atrial remodeling in metabolic syndrome","volume":"13","author":"Lee","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217061_bib146","article-title":"Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis","volume":"2021","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.217061_bib147","first-page":"617","article-title":"Smoking and liver disease","volume":"16","author":"Rutledge","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2021.126954","article-title":"Low concentrations of 4-ABP promote liver carcinogenesis in human liver cells and a zebrafish model","volume":"423","author":"Lin","year":"2022","journal-title":"J. Hazard Mater."},{"issue":"7","key":"10.1016\/j.canlet.2024.217061_bib149","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217061_bib150","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1289\/ehp.0901388","article-title":"Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment","volume":"118","author":"Liu","year":"2010","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.canlet.2024.217061_bib151","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/15376516.2021.2021339","article-title":"Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative stress and cancer development","volume":"32","author":"Cao","year":"2022","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.canlet.2024.217061_bib152","series-title":"Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs, Volumes 1 to 42, IARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans","year":"1987"},{"key":"10.1016\/j.canlet.2024.217061_bib153","unstructured":"912. Aflatoxins (WHO Food Additives Series 40), (n.d.). https:\/\/www.inchem.org\/documents\/jecfa\/jecmono\/v040je16.htm (accessed September 28, 2023)."},{"key":"10.1016\/j.canlet.2024.217061_bib154","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev.publhealth.29.020907.090859","article-title":"Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries","volume":"29","author":"Groopman","year":"2008","journal-title":"Annu. Rev. Publ. Health"},{"key":"10.1016\/j.canlet.2024.217061_bib155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2009.02.057","article-title":"The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy","volume":"286","author":"Gouas","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217061_bib156","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1478-3231.2007.01596.x","article-title":"Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry","volume":"27","author":"Ko","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.canlet.2024.217061_bib157","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17474124.2018.1496016","article-title":"Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI","volume":"12","author":"Golfeyz","year":"2018","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib158","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3350\/cmh.2015.21.3.220","article-title":"The mutational landscape of hepatocellular carcinoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib159","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/cancers13092160","article-title":"Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma","volume":"13","author":"Jang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217061_bib160","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/JHC.S385026","article-title":"Integrated analysis of altered lncRNA, circRNA, microRNA, and mRNA expression in hepatocellular carcinoma carrying TERT promoter mutations","volume":"9","author":"Zhang","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.canlet.2024.217061_bib161","article-title":"Identification of novel characteristics in TP53-mutant hepatocellular carcinoma using bioinformatics","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.canlet.2024.217061_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05958-y","article-title":"Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis","volume":"14","author":"Zhou","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.217061_bib163","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygeno.2013.04.001","article-title":"Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections","volume":"102","author":"Tornesello","year":"2013","journal-title":"Genomics"},{"key":"10.1016\/j.canlet.2024.217061_bib164","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2024.217061_bib165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.24618","article-title":"Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males","volume":"55","author":"White","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2024.217061_bib166","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2019.04.043","article-title":"Hepatocellular carcinoma incidence is decreasing among younger adults in the United States","volume":"18","author":"Rich","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2024.217061_bib167","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cgh.2018.05.039","article-title":"Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma","volume":"17","author":"Rich","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524004555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524004555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:56:33Z","timestamp":1760741793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524004555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":167,"alternative-id":["S0304383524004555"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217061","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217061"}}